PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
65.60%
Growth of 65.60% versus flat Drug Manufacturers - Specialty & Generic revenue. Walter Schloss would verify growth quality.
52.09%
Cost growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 4.99%. Jim Chanos would check for structural cost disadvantages.
109.55%
Growth of 109.55% versus flat Drug Manufacturers - Specialty & Generic gross profit. Walter Schloss would verify quality.
26.54%
Margin expansion while Drug Manufacturers - Specialty & Generic median declines. Peter Lynch would examine competitive advantages.
14.17%
R&D change of 14.17% versus flat Drug Manufacturers - Specialty & Generic spending. Walter Schloss would verify adequacy.
-27.70%
G&A reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate efficiency gains.
2.96%
Marketing expense change of 2.96% versus flat Drug Manufacturers - Specialty & Generic spending. Walter Schloss would verify adequacy.
35090.53%
Other expenses change of 35090.53% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify efficiency.
-19.91%
Operating expenses reduction while Drug Manufacturers - Specialty & Generic median is 4.92%. Seth Klarman would investigate advantages.
19.11%
Total costs growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 5.33%. Jim Chanos would check for waste.
546.34%
Interest expense change of 546.34% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify control.
43.28%
D&A growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 1.77%. Jim Chanos would check for overinvestment.
126.61%
EBITDA growth while Drug Manufacturers - Specialty & Generic declines. Peter Lynch would examine advantages.
263.02%
Margin change of 263.02% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
77.73%
Operating income growth while Drug Manufacturers - Specialty & Generic declines. Peter Lynch would examine advantages.
86.55%
Margin change of 86.55% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
1948.33%
Other expenses change of 1948.33% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify control.
113.92%
Pre-tax income growth while Drug Manufacturers - Specialty & Generic declines. Peter Lynch would examine advantages.
108.40%
Margin change of 108.40% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
103.74%
Tax expense change of 103.74% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify strategy.
115.00%
Net income growth while Drug Manufacturers - Specialty & Generic declines. Peter Lynch would examine advantages.
109.06%
Margin change of 109.06% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
115.13%
EPS change of 115.13% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
114.87%
Diluted EPS change of 114.87% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
0.41%
Share count change of 0.41% versus stable Drug Manufacturers - Specialty & Generic. Walter Schloss would verify approach.
1.04%
Diluted share change of 1.04% versus stable Drug Manufacturers - Specialty & Generic. Walter Schloss would verify approach.